�鶹��

Parent Project Muscular Dystrophy (PPMD) will host a one-hour webinar at 2 p.m. Eastern Time on Wednesday, Sept. 6, that will focus on an upcoming clinical trial exploring gene therapy for Duchenne muscular dystrophy. The webinar will be led by Dr. Jerry Mendell, who, together with fellow researcher Dr. Louise…

In what could be the first step on the long road to finding a potential cure, researchers have found that aberrations in RNA processing are the major cause of congenital myotonic dystrophy (CDM). The study “Disrupted prenatal RNA processing and myogenesis in…

Treadmill training using a voluntary-driven exoskeleton might be a safe approach to improve movement and exercise capacity in patients with limb-girdle muscular dystrophy, according to a small study by researchers at Ruhr University Bochum in Germany. The study, “Treadmill Training with HAL Exoskeleton — A Novel Approach for Symptomatic…

MRIs can pick up subtle muscle changes that standard tests cannot in slowly progressing disorders such as facioscapulohumeral muscular dystrophy, or FSHD, a study reports. The research in the journal PLoS ONE was titled “Long-term follow-up of MRI changes in thigh muscles of patients with Facioscapulohumeral dystrophy: A quantitative…

The chemical structure of a drug can make the entire difference between a success and a failure in drug development. Of two drugs that used the same approach to treat Duchenne muscular dystrophy — Exondys 51 (eteplirsen) and Kyndrisa (drisapersen) — only one became approved. Researchers from The Ohio…

Researchers have found Duchenne muscular dystrophy (�鶹��) patients with heart disease have very high levels of ST2, an interleukin 1 receptor-like 1 protein. That makes this molecule a potential biomarker for cardiac disease in such patients. The study by scientists at Children’s National Health System in Washington, D.C., “Interleukin 1…

Researchers, using a mouse model of Duchenne muscular dystrophy (�鶹��), have discovered that a specific protein, dystrophin, plays an essential role in myelination during postnatal brain development. The protein dystrophin plays a major role in �鶹��. Mutations in the dystrophin gene are a major contributing factor for the development of…

Successful results of Translarna (ataluren) and Emflaza (deflazacort) therapies for Duchenne muscular dystrophy (�鶹��) are highlighted in the 2017 second quarter report by PTC Therapeutics. Orally-administered Translarna is for Duchenne patients to reduce the effect of nonsense mutations in the �鶹�� gene that lead to a lack of…

Synergy HomeCare and the nonprofit Muscular Dystrophy Association (�鶹��) have teamed up in a national partnership to improve quality of life and give more independence to people with neuromuscular disorders. The accord aims to develop a new care guide for newly diagnosed patients and their primary caregivers. The guide will offer…

Many patients with Charcot-Marie-Tooth (CMT) disease, a subtype of muscular dystrophy, undergo surgeries to correct foot deformities. Yet a new study finds that surgeons vary significantly in their choice of procedures for the same operation. The study, “Prevalence and orthopedic management of foot and ankle deformities in Charcot Marie Tooth disease,”…